Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Click here to read full article

In its H1 FY23 results (ending December 2022), Immuron reported revenue of AUD $584,000—a remarkable 153% increase over H1 FY22—with nearly half of that, AUD $287,000, coming from Australian sales. The company credits this performance to strong demand for its over-the-counter oral immunotherapeutic products, Travelan® and Protectyn®. Immuron’s retail reach is reinforced by over 3,500 Australian pharmacies and a leading B2B partner, Passport Health, in the U.S. To support continued growth, the company is launching its own shopfront on Amazon.com in the U.S. during FY23, exploring re-entry into Canadian retail and evaluating expansion into Asian and European markets. Meanwhile, the FDA has approved the IND application for Travelan®, enabling a Phase II controlled-human-infection-model trial to commence this financial year. Immuron also enters H1 FY23 with a robust balance sheet—AUD $18.5 million in cash and cash equivalents as of December 31, 2022.

Proactive: Immuron grows revenue by 153% in H1 FY23 with more growth catalysts lined up